Sarepta TherapeuticsLTS:0L35 +6.14%50 Gross Margin % is 85.12% as of Mar. 2026, which is 2% below its 10-year median of 87.04. GuruFocus rates LTS:0L35 with a GF Score™ of 50/100 and a GF Value™ of $134.89 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 734 Biotechnology companies, Sarepta Therapeutics ranks better than 52.32% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sarepta Therapeutics had a gross margin of 85.12% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Sarepta Therapeutics Gross Margin % Related Terms
Sarepta Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Sarepta Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0L35 vs ZYME, BCAX, INVA: Gross Margin % Comparison
For the Biotechnology subindustry, Sarepta Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sarepta Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Sarepta Therapeutics (LTS:0L35) has a Gross Margin % of 85.12% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Sarepta Therapeutics and its competitors. This is near median its historical median of 87.04. Over the past decade, Sarepta Therapeutics' Gross Margin % has ranged from 61.81 to 98.14. According to the industry distribution chart, Sarepta Therapeutics ranks #350 out of 734 companies in the Biotechnology industry, placing it in the top 47.7%.
Is Sarepta Therapeutics' Gross Margin % too high?
Sarepta Therapeutics' current Gross Margin % of 85.12% is near median its 10-year median of 87.04. Over the past 10 years, this metric has ranged from a low of 61.81 to a high of 98.14. The Biotechnology industry median Gross Margin % is 60.80. Sarepta Therapeutics' value of 85.12% is 40% above this industry median. Based on the distribution chart, Sarepta Therapeutics ranks #350 out of 734 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sarepta Therapeutics has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Gross Margin % compare to ZYME and BCAX?
According to the Biotechnology industry distribution chart, Sarepta Therapeutics ranks #350 out of 734 companies for Gross Margin %. This puts Sarepta Therapeutics in the upper half of its industry. The industry median Gross Margin % is 60.80. Sarepta Therapeutics' value of 85.12% is 40% above this benchmark. Historically, Sarepta Therapeutics' own Gross Margin % has ranged from 61.81 to 98.14 over the past decade. While the company's 10-year median is 87.04 vs. the industry median of 60.80, Sarepta Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.80, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sarepta Therapeutics's current Gross Margin % of 85.12% is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Sarepta Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sarepta Therapeutics's current Gross Margin % is 85.12%, which is near median its own 10-year median of 87.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (LTS:0L35) is currently considered Possible Value Trap. The stock's GF Value™ is $134.89, compared to a current price of $18.16 — trading 86.5% below its estimated fair value. The current Gross Margin % is 85.12%, which is near median its 10-year median of 87.04 and 40% above the Biotechnology industry median of 60.80. Sarepta Therapeutics' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Sarepta Therapeutics (LTS:0L35), the current Gross Margin % is 85.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sarepta Therapeutics (LTS:0L35) Overvalued in 2026?
Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued.
The current stock price of $18.16 is trading 86.5% below its estimated GF Value™ of $134.89.
GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.
Key valuation signals for LTS:0L35:
Gross Margin %: 85.12% (near median its 10-year median of 87.04)
GF Value™: $134.89 vs. price of $18.16 (86.5% below fair value)
Industry Position: 40% above the Biotechnology median (#350 of 734)
No single metric tells the full story. See the LTS:0L35 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
50GF Score
Get the complete analysis for LTS:0L35
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0L35 has been successfully added to your 
